Latest Milos Stories
EMERYVILLE, Calif., May 20, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has received a $25 million milestone payment from Forest Laboratories Holdings Limited related to the development of MDX-8704. MDX-8704, a fixed-dosed combination (FDC) of memantine HCl extended release capsules and donepezil HCl, is being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States....
- The offense of persistently instigating lawsuits, typically groundless ones.
- An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
- Sale or purchase of positions in church or state.